Mesoblast (MSB) H2 2026 earnings summary

Executive summary

• Achieved $115 million net revenue in FY 2026 from RYONCIL's first full U.S. commercial year, establishing a profitable product base and funding late-stage pipeline and manufacturing scale-up.

• RYONCIL is the only FDA-approved mesenchymal stromal cell therapy, with strong market adoption, payer coverage, and expansion plans for adult and pediatric indications.

• Advanced clinical pipeline includes phase III trials for adult SR-aGvHD, chronic low back pain, and chronic heart failure, targeting multi-billion dollar addressable markets.

• Strategic focus on label expansion, new indications (e.g., Duchenne), and global IP protection extending beyond 2044.

• Next-generation technology platforms, including CAR-MSC and OV-MSC, are being developed to diversify the pipeline.

Financial highlights

• FY 2026 net revenue reached $115 million, with total revenue of $120 million and gross profit (excluding amortization) of $110 million.

• Net loss after taxes reduced by 44% year-over-year to $57.5 million.

• R&D investment totaled up to $97.5 million, with $17.3 million on product development and $21.2 million on phase III trials.

• Ended FY 2026 with $103 million in cash; net cash usage for the year was $43.8 million.

• SG&A expenses increased by $18 million due to commercial team expansion and product launch.

Outlook and guidance

• Double-digit revenue growth expected for RYONCIL in the next 12 months, with label expansion underway for adults with SR-aGvHD and children with Duchenne muscular dystrophy.

• Pivotal phase III trial for chronic low back pain completed enrollment; top-line results expected mid-CY2027, with potential BLA filing in H2 2027.

• Continued investment in next-generation cell therapy platforms and strategic partnering opportunities for inflammatory conditions.